Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q39352318)
Watch
English
Receptor tyrosine kinases in cancer escape from BRAF inhibitors
scientific article published on 8 May 2012
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
title
Receptor tyrosine kinases in cancer escape from BRAF inhibitors
(English)
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
author name string
Roger S Lo
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
publication date
8 May 2012
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
published in
Cell Research
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
volume
22
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
page(s)
945-947
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
issue
6
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
exact match
https://scigraph.springernature.com/pub.10.1038/cr.2012.78
0 references
cites work
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3367528
retrieved
11 September 2017
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FCR.2012.78
retrieved
21 January 2018
Identifiers
DOI
10.1038/CR.2012.78
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
PMCID
3367528
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
PubMed ID
22565288
1 reference
stated in
Europe PubMed Central
PMCID
3367528
retrieved
11 September 2017
ResearchGate publication ID
224917724
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
